EquitySector - HealthcareVery High Risk
NAV (17-Jan-25)
Returns (Since Inception)
Fund Size
₹32 Cr
Expense Ratio
0.22%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+32.12%
+30.47% (Cat Avg.)
Since Inception
+29.02%
— (Cat Avg.)
Equity | ₹31.86 Cr | 99.85% |
Others | ₹0.05 Cr | 0.15% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹4.86 Cr | 15.21% |
Cipla Ltd | Equity | ₹2.03 Cr | 6.37% |
Dr Reddy's Laboratories Ltd | Equity | ₹2.02 Cr | 6.32% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.99 Cr | 6.24% |
Divi's Laboratories Ltd | Equity | ₹1.85 Cr | 5.81% |
Apollo Hospitals Enterprise Ltd | Equity | ₹1.75 Cr | 5.49% |
Lupin Ltd | Equity | ₹1.36 Cr | 4.25% |
Fortis Healthcare Ltd | Equity | ₹0.89 Cr | 2.80% |
Aurobindo Pharma Ltd | Equity | ₹0.89 Cr | 2.78% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.76 Cr | 2.38% |
Alkem Laboratories Ltd | Equity | ₹0.71 Cr | 2.22% |
Mankind Pharma Ltd | Equity | ₹0.69 Cr | 2.16% |
Zydus Lifesciences Ltd | Equity | ₹0.58 Cr | 1.83% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.57 Cr | 1.80% |
Laurus Labs Ltd | Equity | ₹0.57 Cr | 1.77% |
Ipca Laboratories Ltd | Equity | ₹0.54 Cr | 1.70% |
Biocon Ltd | Equity | ₹0.39 Cr | 1.21% |
Piramal Pharma Ltd | Equity | ₹0.39 Cr | 1.21% |
Syngene International Ltd | Equity | ₹0.37 Cr | 1.16% |
Abbott India Ltd | Equity | ₹0.36 Cr | 1.14% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹0.35 Cr | 1.09% |
Suven Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 1.08% |
Gland Pharma Ltd | Equity | ₹0.34 Cr | 1.05% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.31 Cr | 0.99% |
Concord Biotech Ltd | Equity | ₹0.31 Cr | 0.97% |
Ajanta Pharma Ltd | Equity | ₹0.3 Cr | 0.93% |
Natco Pharma Ltd | Equity | ₹0.3 Cr | 0.93% |
Neuland Laboratories Limited | Equity | ₹0.28 Cr | 0.88% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.27 Cr | 0.84% |
Dr. Lal PathLabs Ltd | Equity | ₹0.27 Cr | 0.84% |
Wockhardt Ltd | Equity | ₹0.26 Cr | 0.83% |
Poly Medicure Ltd | Equity | ₹0.23 Cr | 0.73% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.22 Cr | 0.68% |
Global Health Ltd | Equity | ₹0.21 Cr | 0.67% |
Granules India Ltd | Equity | ₹0.21 Cr | 0.64% |
Narayana Hrudayalaya Ltd | Equity | ₹0.2 Cr | 0.64% |
Jubilant Pharmova Ltd | Equity | ₹0.2 Cr | 0.63% |
Pfizer Ltd | Equity | ₹0.19 Cr | 0.60% |
Rainbow Childrens Medicare Ltd | Equity | ₹0.18 Cr | 0.57% |
Marksans Pharma Ltd | Equity | ₹0.14 Cr | 0.45% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.44% |
Jupiter Life Line Hospitals Ltd | Equity | ₹0.14 Cr | 0.44% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.14 Cr | 0.43% |
Sanofi India Ltd | Equity | ₹0.13 Cr | 0.41% |
Metropolis Healthcare Ltd | Equity | ₹0.13 Cr | 0.41% |
Caplin Point Laboratories Ltd | Equity | ₹0.12 Cr | 0.38% |
Onesource Specialty Pharma Limited | Equity | ₹0.12 Cr | 0.38% |
Ami Organics Ltd | Equity | ₹0.12 Cr | 0.38% |
Vijaya Diagnostic Centre Ltd | Equity | ₹0.12 Cr | 0.37% |
AstraZeneca Pharma India Ltd | Equity | ₹0.11 Cr | 0.34% |
Strides Pharma Science Ltd | Equity | ₹0.11 Cr | 0.34% |
Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.33% |
Procter & Gamble Health Ltd | Equity | ₹0.1 Cr | 0.31% |
Aarti Pharmalabs Ltd | Equity | ₹0.08 Cr | 0.25% |
Alivus Life Sciences Ltd | Equity | ₹0.07 Cr | 0.23% |
Indegene Ltd | Equity | ₹0.07 Cr | 0.22% |
Kovai Medical Center & Hospital Ltd | Equity | ₹0.07 Cr | 0.21% |
Orchid Pharma Ltd | Equity | ₹0.07 Cr | 0.21% |
Morepen Laboratories Ltd | Equity | ₹0.07 Cr | 0.21% |
FDC Ltd | Equity | ₹0.06 Cr | 0.18% |
Indraprastha Medical Corp Ltd | Equity | ₹0.05 Cr | 0.17% |
Sequent Scientific Ltd | Equity | ₹0.05 Cr | 0.15% |
Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.05 Cr | 0.15% |
Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.15% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹0.05 Cr | 0.15% |
HealthCare Global Enterprises Ltd | Equity | ₹0.05 Cr | 0.15% |
Supriya Lifescience Ltd | Equity | ₹0.05 Cr | 0.14% |
Dishman Carbogen Amics Ltd | Equity | ₹0.04 Cr | 0.13% |
Innova Captab Ltd | Equity | ₹0.04 Cr | 0.13% |
Advanced Enzyme Technologies Ltd | Equity | ₹0.04 Cr | 0.13% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.04 Cr | 0.12% |
Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.12% |
Krsnaa Diagnostics Ltd | Equity | ₹0.04 Cr | 0.12% |
Unichem Laboratories Ltd | Equity | ₹0.04 Cr | 0.11% |
Hikal Ltd | Equity | ₹0.04 Cr | 0.11% |
Thyrocare Technologies Ltd | Equity | ₹0.03 Cr | 0.11% |
Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.10% |
Gufic Biosciences Ltd | Equity | ₹0.03 Cr | 0.09% |
Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.09% |
Bliss GVS Pharma Ltd | Equity | ₹0.03 Cr | 0.08% |
Gujarat Themis Biosyn Ltd | Equity | ₹0.02 Cr | 0.07% |
RPG Life Sciences Ltd | Equity | ₹0.02 Cr | 0.07% |
IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.07% |
Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.07% |
Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.07% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.07% |
Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.07% |
Suven Life Sciences Ltd | Equity | ₹0.02 Cr | 0.06% |
Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.06% |
Themis Medicare Ltd | Equity | ₹0.02 Cr | 0.06% |
Lincoln Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.06% |
Vimta Labs Ltd | Equity | ₹0.02 Cr | 0.05% |
SMS Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.05% |
Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
Novartis India Ltd | Equity | ₹0.01 Cr | 0.05% |
Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
NGL Fine-Chem Ltd | Equity | ₹0.01 Cr | 0.02% |
KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
Large Cap Stocks
45.58%
Mid Cap Stocks
28.64%
Small Cap Stocks
24.36%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹31.3 Cr | 98.08% |
Basic Materials | ₹0.16 Cr | 0.51% |
Standard Deviation
This fund
--
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
ISIN INF247L01BB1 | Expense Ratio 0.22% | Exit Load - | Fund Size ₹32 Cr | Age 2 years 5 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 32.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 25.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 24.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 30.6% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 32.2% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 29.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 31.1% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 29.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 29.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 29.7% |
Total AUM
₹85,154 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
NAV (17-Jan-25)
Returns (Since Inception)
Fund Size
₹32 Cr
Expense Ratio
0.22%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+32.12%
+30.47% (Cat Avg.)
Since Inception
+29.02%
— (Cat Avg.)
Equity | ₹31.86 Cr | 99.85% |
Others | ₹0.05 Cr | 0.15% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹4.86 Cr | 15.21% |
Cipla Ltd | Equity | ₹2.03 Cr | 6.37% |
Dr Reddy's Laboratories Ltd | Equity | ₹2.02 Cr | 6.32% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.99 Cr | 6.24% |
Divi's Laboratories Ltd | Equity | ₹1.85 Cr | 5.81% |
Apollo Hospitals Enterprise Ltd | Equity | ₹1.75 Cr | 5.49% |
Lupin Ltd | Equity | ₹1.36 Cr | 4.25% |
Fortis Healthcare Ltd | Equity | ₹0.89 Cr | 2.80% |
Aurobindo Pharma Ltd | Equity | ₹0.89 Cr | 2.78% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.76 Cr | 2.38% |
Alkem Laboratories Ltd | Equity | ₹0.71 Cr | 2.22% |
Mankind Pharma Ltd | Equity | ₹0.69 Cr | 2.16% |
Zydus Lifesciences Ltd | Equity | ₹0.58 Cr | 1.83% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.57 Cr | 1.80% |
Laurus Labs Ltd | Equity | ₹0.57 Cr | 1.77% |
Ipca Laboratories Ltd | Equity | ₹0.54 Cr | 1.70% |
Biocon Ltd | Equity | ₹0.39 Cr | 1.21% |
Piramal Pharma Ltd | Equity | ₹0.39 Cr | 1.21% |
Syngene International Ltd | Equity | ₹0.37 Cr | 1.16% |
Abbott India Ltd | Equity | ₹0.36 Cr | 1.14% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹0.35 Cr | 1.09% |
Suven Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 1.08% |
Gland Pharma Ltd | Equity | ₹0.34 Cr | 1.05% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.31 Cr | 0.99% |
Concord Biotech Ltd | Equity | ₹0.31 Cr | 0.97% |
Ajanta Pharma Ltd | Equity | ₹0.3 Cr | 0.93% |
Natco Pharma Ltd | Equity | ₹0.3 Cr | 0.93% |
Neuland Laboratories Limited | Equity | ₹0.28 Cr | 0.88% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.27 Cr | 0.84% |
Dr. Lal PathLabs Ltd | Equity | ₹0.27 Cr | 0.84% |
Wockhardt Ltd | Equity | ₹0.26 Cr | 0.83% |
Poly Medicure Ltd | Equity | ₹0.23 Cr | 0.73% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.22 Cr | 0.68% |
Global Health Ltd | Equity | ₹0.21 Cr | 0.67% |
Granules India Ltd | Equity | ₹0.21 Cr | 0.64% |
Narayana Hrudayalaya Ltd | Equity | ₹0.2 Cr | 0.64% |
Jubilant Pharmova Ltd | Equity | ₹0.2 Cr | 0.63% |
Pfizer Ltd | Equity | ₹0.19 Cr | 0.60% |
Rainbow Childrens Medicare Ltd | Equity | ₹0.18 Cr | 0.57% |
Marksans Pharma Ltd | Equity | ₹0.14 Cr | 0.45% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.44% |
Jupiter Life Line Hospitals Ltd | Equity | ₹0.14 Cr | 0.44% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.14 Cr | 0.43% |
Sanofi India Ltd | Equity | ₹0.13 Cr | 0.41% |
Metropolis Healthcare Ltd | Equity | ₹0.13 Cr | 0.41% |
Caplin Point Laboratories Ltd | Equity | ₹0.12 Cr | 0.38% |
Onesource Specialty Pharma Limited | Equity | ₹0.12 Cr | 0.38% |
Ami Organics Ltd | Equity | ₹0.12 Cr | 0.38% |
Vijaya Diagnostic Centre Ltd | Equity | ₹0.12 Cr | 0.37% |
AstraZeneca Pharma India Ltd | Equity | ₹0.11 Cr | 0.34% |
Strides Pharma Science Ltd | Equity | ₹0.11 Cr | 0.34% |
Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.33% |
Procter & Gamble Health Ltd | Equity | ₹0.1 Cr | 0.31% |
Aarti Pharmalabs Ltd | Equity | ₹0.08 Cr | 0.25% |
Alivus Life Sciences Ltd | Equity | ₹0.07 Cr | 0.23% |
Indegene Ltd | Equity | ₹0.07 Cr | 0.22% |
Kovai Medical Center & Hospital Ltd | Equity | ₹0.07 Cr | 0.21% |
Orchid Pharma Ltd | Equity | ₹0.07 Cr | 0.21% |
Morepen Laboratories Ltd | Equity | ₹0.07 Cr | 0.21% |
FDC Ltd | Equity | ₹0.06 Cr | 0.18% |
Indraprastha Medical Corp Ltd | Equity | ₹0.05 Cr | 0.17% |
Sequent Scientific Ltd | Equity | ₹0.05 Cr | 0.15% |
Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.05 Cr | 0.15% |
Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.15% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹0.05 Cr | 0.15% |
HealthCare Global Enterprises Ltd | Equity | ₹0.05 Cr | 0.15% |
Supriya Lifescience Ltd | Equity | ₹0.05 Cr | 0.14% |
Dishman Carbogen Amics Ltd | Equity | ₹0.04 Cr | 0.13% |
Innova Captab Ltd | Equity | ₹0.04 Cr | 0.13% |
Advanced Enzyme Technologies Ltd | Equity | ₹0.04 Cr | 0.13% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.04 Cr | 0.12% |
Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.12% |
Krsnaa Diagnostics Ltd | Equity | ₹0.04 Cr | 0.12% |
Unichem Laboratories Ltd | Equity | ₹0.04 Cr | 0.11% |
Hikal Ltd | Equity | ₹0.04 Cr | 0.11% |
Thyrocare Technologies Ltd | Equity | ₹0.03 Cr | 0.11% |
Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.10% |
Gufic Biosciences Ltd | Equity | ₹0.03 Cr | 0.09% |
Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.09% |
Bliss GVS Pharma Ltd | Equity | ₹0.03 Cr | 0.08% |
Gujarat Themis Biosyn Ltd | Equity | ₹0.02 Cr | 0.07% |
RPG Life Sciences Ltd | Equity | ₹0.02 Cr | 0.07% |
IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.07% |
Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.07% |
Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.07% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.07% |
Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.07% |
Suven Life Sciences Ltd | Equity | ₹0.02 Cr | 0.06% |
Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.06% |
Themis Medicare Ltd | Equity | ₹0.02 Cr | 0.06% |
Lincoln Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.06% |
Vimta Labs Ltd | Equity | ₹0.02 Cr | 0.05% |
SMS Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.05% |
Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
Novartis India Ltd | Equity | ₹0.01 Cr | 0.05% |
Kopran Ltd | Equity | ₹0.01 Cr | 0.04% |
GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
NGL Fine-Chem Ltd | Equity | ₹0.01 Cr | 0.02% |
KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
Large Cap Stocks
45.58%
Mid Cap Stocks
28.64%
Small Cap Stocks
24.36%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹31.3 Cr | 98.08% |
Basic Materials | ₹0.16 Cr | 0.51% |
Standard Deviation
This fund
--
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
ISIN INF247L01BB1 | Expense Ratio 0.22% | Exit Load - | Fund Size ₹32 Cr | Age 2 years 5 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 32.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 25.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 24.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 30.6% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 32.2% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 29.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 31.1% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 29.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 29.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 29.7% |
Total AUM
₹85,154 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Get your portfolio reviewed by experts